Human monoclonal antibodies against CD20
US8529902B2 · kind B2 · utility
16Cited by
32References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 17, 2003 |
| Grant date | Sep 10, 2013 |
| Priority date | — |
| Expiry date | Aug 2, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Isolated human monoclonal antibodies which bind to and inhibit human CD20, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.